Background SARS-CoV-2 strains healthcare capacity . Better risk stratification, with discharge of patients with a predicted mild disease trajectory can ease this burden . Elevated blood soluble urokinase plasminogen activator receptor (suPAR) has previously been shown associated with risk of intubation in confirmed COVID-19 patients . Objective To evaluate if point-of-care measures of suPAR in patients presenting at the emergency department (ED) with symptoms of COVID-19 can identify patients that can be safely discharged . Methods Observational cohort study including all patients in the ED with symptoms of COVID-19 from March 19th to April 3rd , 2020 . Soluble urokinase plasminogen activator receptor was measured at first presentation . Review of electronic patient records 14 days after admission were used to assess disease trajectory . Primary endpoints were mild, moderate, severe, or very severe trajectory . The predictive value of suPAR, National early warning score (NEWS), C-reactive protein (CRP), and duration of symptoms (DOS) was calculated using receiver operating characteristics (ROC). Results Of 386 patients , 171 (44 %) patients had a mild disease trajectory , 79 (20 %) a moderate , 63 (16 %) a severe, and 73 (19 %) a very severe disease trajectory . Low suPAR was a strong marker of mild disease trajectory . Results suggest a cut-off for discharge for suPAR <2.0 ng/ml if suPAR is used as a single parameter, and 3.0 ng/ml when combined with NEWS= <4 and CRP <10 mg/l- Conclusion suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. suPAR can be used even before SARS-CoV-2 status is known.